5.1.2 Treatment Phase ...................................................................................... 5.1.2.1 Monotherapy Dose Escalation (Preliminary Safety Cohorts and Part A) ................................................................................................... 5.1.2.2 BMS-986226 and Nivolumab Combination Therapy Cohort (Parts B1 and B2) ............................................................................................ 5.1.2.3 BMS-986226 and Ipilimumab Combination Therapy Cohort (Parts C1 and C2) ............................................................................................ 5.1.2.4 Combination Expansion Arms (Parts D and E) ..............................